Mark A. Meltz
CIK: 0001771329
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LYEL
Lyell Immunopharma, Inc.
Officer
Discretionary Trading P&L
Holdings
About Meltz Mark A
Meltz Mark A (SEC CIK 0001771329) files insider reports with the SEC as General Counsel of Lyell Immunopharma, Inc. (LYEL).
Signal8 holds 3 ownership filings by Meltz Mark A (1 Form 3, 2 Form 4), filed between Jun 11, 2025 and Feb 11, 2026. Those filings report 2 transactions, from Jun 9, 2025 to Feb 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Meltz Mark A's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Meltz Mark A
Other insiders filing for Lyell Immunopharma, Inc. (LYEL)
- Aguirre Jarrad Mattieu, Chief Medical Officer
- Shook David, Chief Medical Officer
- Seely Lynn, President and CEO
- Hill Stephen J., Chief Operating Officer
- Lee Gary K., Chief Scientific Officer
- Bulis Veronica Sanchez, VP, Corporate Controller